
Why are Dr. Reddy’s shares trading higher today
Dr. Reddy’s Laboratories has received the U.S. FDA approval to launch Fesoterodine Fumarate extended-release tablets in the American market
Dr. Reddy’s Laboratories has received the U.S. FDA approval to launch Fesoterodine Fumarate extended-release tablets in the American market
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
The BSE Sensex and the NSE Nifty are poised to open lower on Wednesday amid mixed global cues as well as growing Covid-19 cases surge across the country.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
Prices of vaccines may crash in the next few months. The vaccine makers will have to strike while the iron is hot.
As the world awaits a panacea for Covid-19, pharma companies have their feet firmly on the accelerator to get people a safe vaccine to stem the spiral of death and illness looming over humanity.
The Nifty pharma index moved up sharply today, in what was a tepid trading day. The gains came as a surprise as top Indian companies faced new charges of price fixing in the US generic market.